April 30, 2014
The Third Circuit on Wednesday upheld a lower court ruling that generic manufacturers of equivalents of the bone drug Fosamax could not be held liable for injuries supposedly incurred by drug users, concluding that the state-law claims asserted in the suit were preempted by federal law.
December 18, 2013
The Third Circuit on Wednesday questioned whether it had jurisdiction to hear an appeal in a case that seeks to hold generic-drug manufacturers responsible for injuries allegedly caused by their versions of the bone drug Fosamax.
September 24, 2013
A federal judge wrongfully used the U.S. Supreme Court's Pliva Inc. v. Mensing ruling to preempt design defect claims against generic-drug makers in multidistrict litigation over the safety of Merck & Co.'s bone drug Fosamax, according to a briefing filed Monday with the Third Circuit.